Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,958 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT04722146

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of California San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Winship Cancer Institute Emory University Atlanta, Georgia, United States
View all 27 locations
View Trial Details
Active, Not Recruiting

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

NCT06139406

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • Austin Hospital Heidelberg, Australia
  • The Alfred Hospital Melbourne, Australia
  • Linear Clinical Research Ltd Nedlands, Australia
  • Scientia Clinical Research Randwick, Australia
View Trial Details
Active, Not Recruiting

A Study of Daratumumab

NCT05438043

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Miami Sylvester Cancer Center Miami, Florida, United States
  • Emory University Atlanta, Georgia, United States
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
  • Barnes-jewish Hospital St Louis, Missouri, United States
View all 92 locations
View Trial Details
Active, Not Recruiting

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05421663

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • City of Hope Duarte, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • University of Iowa Hospital and Clinics Iowa City, Iowa, United States
  • University of Kentucky Medical Center Lexington, Kentucky, United States
View all 32 locations
View Trial Details
Active, Not Recruiting

A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

NCT06660563

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • Concord Hospital Concord, Australia
  • St Vincents Hospital Melbourne Fitzroy, Australia
  • Macquarie University Hospital North Ryde, Australia
  • Hosp Univ Vall D Hebron Barcelona, Spain
View Trial Details
Active, Not Recruiting

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Cleveland Clinic Florida Weston, Florida, United States
  • Augusta University- Georgia Cancer Center Augusta, Georgia, United States
View all 53 locations
View Trial Details
Active, Not Recruiting

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

NCT07387471

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +18 more
Locations
  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 279178 Nagoya, Aichi-ken, Japan
  • Nagoya City University Hospital /ID# 277580 Nagoya, Aichi-ken, Japan
  • University of Fukui Hospital /ID# 279173 Yoshida-gun, Fukui, Japan
  • Kyushu University Hospital /ID# 277582 Fukuoka, Japan
View all 17 locations
View Trial Details
Active, Not Recruiting

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

NCT03888105

Conditions
B-cell Non-Hodgkin Lymphoma (B-NHL), Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Rush University Medical Center Chicago, Illinois, United States
  • University of Iowa Iowa City, Iowa, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Tufts Medical Center Boston, Massachusetts, United States
View all 119 locations
View Trial Details
Active, Not Recruiting

Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia

NCT06323447

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Diffuse Large B Cell Lymphoma, +18 more
Locations
  • University of Hawaii Cancer Center Honolulu, Hawaii, United States
  • Norton Healthcare Cancer Center Louisville, Kentucky, United States
  • Massachussetts General Hospital Boston, Massachusetts, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
View Trial Details
Active, Not Recruiting

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

NCT02978625

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Anaplastic Large Cell Lymphoma, ALK-Positive, +86 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Keck Medical Center of USC Pasadena Pasadena, California, United States
View all 36 locations
View Trial Details

Related conditions